Aldosterone upregulates Ca(2+) current in adult rat cardiomyocytes

J P Bénitah1, G Vassort

  • 1Laboratoire de Physiopathologie Cardiovasculaire, INSERM U-390, IFR3, Montpellier, France. benitah@welchlink.welch.jhu.edu

Circulation Research
|December 11, 1999
PubMed

Insights

Aldosterone significantly increases cardiomyocyte calcium current (I(Ca)) density over 24 hours, suggesting a genomic mechanism. This finding offers insights into aldosterone

Area of Science:

  • Cardiovascular Physiology
  • Molecular Endocrinology
  • Cardiac Electrophysiology

Background:

  • Aldosterone contributes to left ventricular hypertrophy and heart failure, independent of blood pressure.
  • Limited data exists on aldosterone's direct effects on cardiomyocyte electrical activity.

Purpose of the Study:

  • To investigate the role of aldosterone in modulating whole-cell calcium current (I(Ca)) in adult rat ventricular myocytes.
  • To elucidate the mechanisms underlying aldosterone's influence on cardiac electrophysiology.

Main Methods:

  • Patch-clamp technique was employed to measure I(Ca) in isolated adult rat ventricular myocytes.
  • Cells were treated with aldosterone (1 µmol/L) for varying durations (up to 24 hours).
  • Effects were assessed in the presence of spironolactone, actinomycin D, and cycloheximide.

Main Results:

  • Long-term (24 hours) aldosterone exposure significantly increased I(Ca) density.
  • Short-term (≤6 hours) aldosterone exposure showed no significant effect on I(Ca).
  • Spironolactone, actinomycin D, and cycloheximide blocked the aldosterone-induced increase in I(Ca) density.

Conclusions:

  • Aldosterone exerts a long-latency, genomic effect on cardiomyocyte I(Ca) density, likely via increased channel expression.
  • This aldosterone-mediated genomic action may contribute to the elevated I(Ca) observed during cardiac remodeling.
  • Findings highlight a novel mechanism linking mineralocorticoid signaling to cardiac electrical remodeling.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...